Key result
Refralon successfully achieved pharmacological cardioversion in two patients with persistent atrial fibrillation after pulmonary vein cryoablation and ineffective electrical cardioversion.
Why the study?
Does refralon improve pharmacological cardioversion in patients with persistent atrial fibrillation after pulmonary vein cryoablation and ineffective electrical cardioversion?
Does refralon improve pharmacological cardioversion in patients with persistent atrial fibrillation after pulmonary vein cryoablation and ineffective electrical cardioversion?
Refralon demonstrated successful pharmacological cardioversion in two patients with persistent atrial fibrillation following cryoablation and failed electrical cardioversion.
Refralon enabled cardioversion after failed electrical attempts in two post-cryoablation cases; hypothesis-generating and requires prospective trials before any practice consideration.
We present two cases of successful pharmacological cardioversion using antiarrhythmic drug refralon in patients with persistent atrial fibrillation after pulmonary vein cryoablation and ineffective electrical cardioversion. These clinical cases represent the first experience of successful use of refralon in patients who underwent cryoablation.
No takes yet. Share an insight, caveat, or question.
Zelberg et al. (2021) studied this question. Refralon successfully achieved pharmacological cardioversion in two patients with persistent atrial fibrillation after pulmonary vein cryoablation and ineffective electrical cardioversion.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: